Latest news

Thumbnail image for Shire turns down Takeda’s advances

Shire turns down Takeda’s advances

Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion.

20th April 2018

Thumbnail image for FDA advisors back approval of GW’s Epidiolex

FDA advisors back approval of GW’s Epidiolex

As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

20th April 2018

Thumbnail image for US widens use of AZ’ Tagrisso in lung cancer

US widens use of AZ’ Tagrisso in lung cancer

AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.

20th April 2018

Thumbnail image for Final NHS nod for Roche’s RoActemra

Final NHS nod for Roche’s RoActemra

Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.

19th April 2018

Thumbnail image for GW’s Epidiolex takes a leap toward US approval

GW’s Epidiolex takes a leap toward US approval

Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.

19th April 2018

Thumbnail image for MPs slate rate of progress on NHS cyber security

MPs slate rate of progress on NHS cyber security

MPs have criticised the government’s slow response to last year’s WannaCry attack on the NHS, and warn there is much work to be done to improve cyber security if damage from the next attack is to be minimised.

19th April 2018

Thumbnail image for Rigel bags first FDA approval

Rigel bags first FDA approval

Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.

18th April 2018

Thumbnail image for US expands use of Shire’s Vonvendi

US expands use of Shire’s Vonvendi

US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD).

18th April 2018

Thumbnail image for Amgen, Novartis’ migraine therapy impresses again

Amgen, Novartis’ migraine therapy impresses again

Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.

18th April 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download